U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H25N5O4
Molecular Weight 387.4336
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TERAZOSIN

SMILES

COc1cc2c(cc1OC)nc([nH]c2=N)N3CCN(CC3)C(=O)C4CCCO4

InChI

InChIKey=VCKUSRYTPJJLNI-UHFFFAOYSA-N
InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)

HIDE SMILES / InChI

Molecular Formula C19H25N5O4
Molecular Weight 387.4336
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/10503165

Terazosin (marketed as Hytrin or Zayasel) is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH). It also acts to lower blood pressure, so it is a drug of choice for men with hypertension and prostate enlargement. All three receptor subtypes appear to be involved in maintaining vascular tone. The α1A-receptor maintains basal vascular tone while the α1B-receptor mediates the vasocontrictory effects of exogenous α1-agonists. Activation of α1-receptors activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A2, and D. This results in mobilization of Ca2+ from intracellular stores, activation of mitogen-activated kinase and PI3 kinase pathways and subsequent vasoconstriction.

CNS Activity

Curator's Comment:: Known to be CNS penetrant in rats Human data not available

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
TERAZOSIN HYDROCHLORIDE

Approved Use

are used to treat high blood preassure (hypertension); are also used to treat benign prostatic hyperplasia (BPH) in men

Launch Date

9.5022717E11
Primary
TERAZOSIN HYDROCHLORIDE

Approved Use

are used to treat high blood preassure (hypertension); are also used to treat benign prostatic hyperplasia (BPH) in men

Launch Date

9.501408E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
48 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERAZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
37 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERAZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
408 ng × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERAZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
418 ng × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERAZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.4 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERAZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
9.5 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERAZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
8%
TERAZOSIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
80 mg 1 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1169
unhealthy
n = 14
Health Status: unhealthy
Condition: Hypertension
Population Size: 14
Sources: Page: p.1169
Disc. AE: Dizziness...
AEs leading to
discontinuation/dose reduction:
Dizziness
Sources: Page: p.1169
80 mg 1 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.903
unhealthy
n = 37
Health Status: unhealthy
Condition: Hypertension
Population Size: 37
Sources: Page: p.903
Disc. AE: Syncope...
AEs leading to
discontinuation/dose reduction:
Syncope (2.7%)
Sources: Page: p.903
20 mg 1 times / day multiple, oral
MTD
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.9
unhealthy
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia|Hypertension
Sources: Page: p.9
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia|Hypertension
Sources: Page: p.6
Other AEs: Syncope, Postural hypotension...
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Disc. AE: Dizziness, Asthenia...
AEs leading to
discontinuation/dose reduction:
Dizziness (6.7%)
Asthenia (3.8%)
Somnolence (2%)
Chest pain (1.6%)
Headache (1.2%)
Dyspnea (1.2%)
Prostate carcinoma (1%)
Sources: Page: p.409
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Disc. AE: Fever, Headache...
AEs leading to
discontinuation/dose reduction:
Fever (0.5%)
Headache (1.1%)
Postural hypotension (0.5%)
Syncope (0.5%)
Nausea (0.5%)
Dizziness (2%)
Vertigo (0.5%)
Dyspnea (0.5%)
Blurred vision (0.6%)
Amblyopia (0.6%)
Urinary tract infection (0.5%)
Sources: Page: p.12
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Disc. AE: Asthenia, Headache...
AEs leading to
discontinuation/dose reduction:
Asthenia (1.6%)
Headache (1.3%)
Palpitations (1.4%)
Postural hypotension (0.5%)
Syncope (0.5%)
Tachycardia (0.6%)
Nausea (0.8%)
Peripheral edema (0.6%)
Dizziness (3.1%)
Paresthesia (0.8%)
Somnolence (0.6%)
Dyspnea (0.9%)
Nasal congestion (0.6%)
Blurred vision (0.6%)
Sources: Page: p.16
AEs

AEs

AESignificanceDosePopulation
Dizziness Disc. AE
80 mg 1 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1169
unhealthy
n = 14
Health Status: unhealthy
Condition: Hypertension
Population Size: 14
Sources: Page: p.1169
Syncope 2.7%
Disc. AE
80 mg 1 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.903
unhealthy
n = 37
Health Status: unhealthy
Condition: Hypertension
Population Size: 37
Sources: Page: p.903
Postural hypotension
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia|Hypertension
Sources: Page: p.6
Priapism
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia|Hypertension
Sources: Page: p.6
Syncope
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia|Hypertension
Sources: Page: p.6
Prostate carcinoma 1%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Dyspnea 1.2%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Headache 1.2%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Chest pain 1.6%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Somnolence 2%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Asthenia 3.8%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Dizziness 6.7%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Dyspnea 0.5%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Fever 0.5%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Nausea 0.5%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Postural hypotension 0.5%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Syncope 0.5%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Urinary tract infection 0.5%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Vertigo 0.5%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Amblyopia 0.6%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Blurred vision 0.6%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Headache 1.1%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Dizziness 2%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Postural hypotension 0.5%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Syncope 0.5%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Blurred vision 0.6%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Nasal congestion 0.6%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Peripheral edema 0.6%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Somnolence 0.6%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Tachycardia 0.6%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Nausea 0.8%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Paresthesia 0.8%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Dyspnea 0.9%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Headache 1.3%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Palpitations 1.4%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Asthenia 1.6%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Dizziness 3.1%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
High-performance liquid chromatographic analysis and pharmacokinetics of terazosin in healthy volunteers.
2001
5alpha-reductase inhibitors: what role should they play?
2001 Dec
Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component.
2002
Apoptotic and proliferative index after Alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia.
2002
Tamsulosin: an update of its role in the management of lower urinary tract symptoms.
2002
Role of supraspinal alpha1-adrenoceptors for voiding in conscious rats with and without bladder outlet obstruction.
2002 Apr
Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms.
2002 Apr
Hypertension in L-NAME-treated diabetic rats depends on an intact sympathetic nervous system.
2002 Apr
Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials.
2002 Dec 12
Chronic cardiovascular and renal actions of leptin: role of adrenergic activity.
2002 Feb
The use of alpha-adrenoceptor antagonists in lower urinary tract disease.
2002 Feb
[Chiral separation and preparation of three new antagonists of alpha 1-adrenoceptors by chiral mobile phase HPLC].
2002 Jun
Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia.
2002 Jun
The efficacy of terazosin for treating benign prostatic hyperplasia: a multicentre clinical trial.
2002 May
Mice expressing the alpha(1B)-adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation.
2002 Nov
Influence of new evidence on prescription patterns.
2002 Nov-Dec
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
2002 Nov-Dec
Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects.
2002 Oct
[alpha 1-receptor blockade in therapy of benign prostatic hyperplasia syndrome. Correct dosing for optimal effectiveness].
2002 Sep
[Use of alpha1-adrenergic blockaders in voiding disorders in women].
2002 Sep-Oct
[Results of monotherapy with terazosin (kornam) in chronic infectious prostatitis patients].
2002 Sep-Oct
[Urodynamic criteria of predicting efficacy of therapy with alpha1-adrenergic blockaders in patients with benign prostatic hyperplasia].
2002 Sep-Oct
[Comparative evaluation of the efficacy of using terazosin and tamsulosin in patients with benign prostatic hyperplasia].
2002 Sep-Oct
Impact of alpha1-blockers in men with spinal cord injury and upper tract stasis.
2002 Summer
[Serum nitric oxide and D-dimer before and after administering antihypertensive drugs in essential hypertension].
2003 Aug
Use of alpha-blockers and the risk of hip/femur fractures.
2003 Dec
Immobility from administration of the alpha1-adrenergic antagonist, terazosin, in the IVth ventricle in rats.
2003 Dec 26
Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells.
2003 Feb
Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial.
2003 Feb
[Hepatotoxicity induced by terazosin].
2003 Feb 1
Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of alpha1-adrenergic blockade.
2003 Jan 7
[Results of treatment of irritative symptoms and urinary retention in patients 1 year after radical retropubic prostatectomy].
2003 Jan-Feb
Pharmacological characterization of unique prazosin-binding sites in human kidney.
2003 Jul
Effects of intravenous and infravesical administration of suramin, terazosin and BMY 7378 on bladder instability in conscious rats with bladder outlet obstruction.
2003 Jul
Role of epinephrine stimulation of CNS alpha1-adrenoceptors in motor activity in mice.
2003 Jul
Comparison of finasteride and alpha-blockers as independent risk factors for erectile dysfunction.
2003 Jul-Aug
Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
2003 Mar
The ICH guidance in practice: stress decomposition studies on three piperazinyl quinazoline adrenergic receptor-blocking agents and comparison of their degradation behaviour.
2003 Mar 26
Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction.
2003 May 19
Review: terazosin improves urologic symptoms in benign prostatic hyperplasia.
2003 May-Jun
Growth inhibiting effects of terazosin on androgen-independent prostate cancer cell lines.
2003 Nov
Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia.
2003 Nov
Hormonal and morphologic evaluation of the effects of antiandrogens on the blood supply of the rat prostate.
2003 Nov
Pharmacological characterization of isolated human prostate.
2003 Sep
[Pharmacologic treatment of benign prostatic hyperplasia].
2003 Sep 14
The alpha1-adrenoceptor antagonist terazosin induces prostate cancer cell death through a p53 and Rb independent pathway.
2003 Sep-Oct
Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs).
2004 Feb 23
Validated specific HPLC methods for determination of prazosin, terazosin and doxazosin in the presence of degradation products formed under ICH-recommended stress conditions.
2004 Jan 27
Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia.
2004 Mar
Measurement of low-dose active pharmaceutical ingredient in a pharmaceutical blend using frequency-domain photon migration.
2004 Mar
Patents

Sample Use Guides

In Vivo Use Guide
for Hypertension: Initial dose: 1 mg orally once a day at bedtime; Maintenance dose: 1-5 mg orally once a day. Maximum dose: 20 mg per day. Usual Adult Dose for Benign Prostatic Hyperplasia: Initial dose: 1 mg orally once a day at bedtime. Maintenance dose: Increased in a stepwise fashion to 2 mg, 5 mg, or 10 mg once a day to achieve desired improvement of symptoms.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment:: TZ (terazosin) has a new protein target, Pgk1 (phosphoglycerate kinase 1), and reveal its corresponding biological effect. As a clinical drug, TZ may be quickly translated into treatments for diseases including stroke and sepsis.
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 01:53:01 UTC 2021
Edited
by admin
on Sat Jun 26 01:53:01 UTC 2021
Record UNII
8L5014XET7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TERAZOSIN
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
TERAZOSIN [MI]
Common Name English
TERAZOSIN [INN]
Common Name English
TERAZOCIN
Systematic Name English
TERAZOSABB
Brand Name English
TERAZOSIN [VANDF]
Common Name English
TERAZOSIN [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-VATC QG04CA03
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
WHO-ATC G04CA03
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
NDF-RT N0000000099
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
LIVERTOX 936
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
NDF-RT N0000175553
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
NCI_THESAURUS C29713
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
Code System Code Type Description
RXCUI
37798
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
PRIMARY RxNorm
IUPHAR
7302
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
PRIMARY
DRUG CENTRAL
3584
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
PRIMARY
ChEMBL
CHEMBL611
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
PRIMARY
DRUG BANK
DB01162
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
PRIMARY
NCI_THESAURUS
C61964
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
PRIMARY
INN
4843
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
PRIMARY
EPA CompTox
63590-64-7
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
PRIMARY
MESH
C041226
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
PRIMARY
EVMPD
SUB10907MIG
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
PRIMARY
FDA UNII
8L5014XET7
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
PRIMARY
PUBCHEM
5401
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
PRIMARY
MERCK INDEX
M10567
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
PRIMARY Merck Index
WIKIPEDIA
TERAZOSIN
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
PRIMARY
CAS
63590-64-7
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
PRIMARY
LACTMED
Terazosin
Created by admin on Sat Jun 26 01:53:01 UTC 2021 , Edited by admin on Sat Jun 26 01:53:01 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC